drug · antibody
denecimig
pre_registrationupdated 6mo agoby Novo Nordisk AS🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Phase 3, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
News(4)
- FDA extends review of Novo’s hemophilia A drug, citing manufacturing issuesDespite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.biospace · 1mo ago
- FDA delays Novo’s hemophilia A drug review over factory issuesUS regulators have extended their review of Novo's hemophilia A injection denecimig because of issues at an unnamed manufacturing facility. The FDA attributed the delay to “ongoing facility remedia…endpoints · 1mo ago
- STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and moreVaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merckstat · 1mo ago
- Novo struggles to appease restive investors with consumer plans, blockbuster ambitionsWith reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a…fiercebiotech · 1mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that